Stefan Kloiber

Research Synopsis

Dr. Kloiber’s clinical expertise and research focuses on mood and anxiety disorders. A major focus of Dr. Kloiber's clinical research is to investigate novel neurobiological systems including the brain endocannabinoid system in mood and anxiety disorders as well as to explore novel treatment approaches through clinical trials with a specific interest in neurobiological and clinical effects of cannabinoids. Research projects in this field include clinical studies evaluating the effects of cannabinoids, e.g. cannabidiol (CBD) and projects to understand perceptions and motivations for cannabis use in mood and anxiety disorders, as well as neuroimaging / positron emission tomography (PET) studies evaluating the brain endocannabinoid system in the with mood and anxiety disorders, healthy controls and the effect of cannabinoids such as THC on the brain endocannabinoid system.

Another aspect of Dr. Kloiber’s work is focused on improving treatment of mood and anxiety disorders by standardizing and individualizing therapy through Integrated Care Pathways (ICPs) and biomarker research combining various strategies such as genomics, neuroendocrinology, metabolomics, digital behavioral phenotyping and psychophysiology. With this approach Dr. Kloiber aims to detect individual biological signatures for prediction of treatment response, prevention of adverse events, and subclassification of mood and anxiety disorders.

Dr. Kloiber’s research has been funded by the Canadian Institutes of Health Research (CIHR), the Canadian Centre on Substance Use and Addiction (CCSA), the Ministry of Health of Ontario, the Labatt Family Innovation Fund in Brain Health, the Max Bell Foundation, or the Caskey Francis Family Award in Clinical Research. He is the principal investigator or co-investigator on multiple clinical studies and neuroimaging studies in mood and anxiety disorders.